Physician profile
Nadia Abelhad
NPI 1619400801
$13,200.86
in general payments reported to CMS, 2019-2025
34 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $588 · 2021: $3,309 · 2022: $3,385 · 2023: $2,254 · 2024: $1,620 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,964 · Travel and Lodging: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,964.10 |
| Travel and Lodging | $814.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $4,684.99 | 2021-2023 | Acticor 7 Vr-T Dx |
| Boston Scientific Corporation | $1,415.31 | 2021-2025 | Versacross Access Solution, Farapulse, Versacross Steerable Access Solution |
| Abbott Laboratories | $841.40 | 2021-2025 | Ensite, Gallant, Perclose Proglide |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $806.69 | 2020-2025 | Lifevest |
| Edwards Lifesciences Corporation | $735.39 | 2024-2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $486.75 | 2020-2022 | |
| Shockwave Medical, INC | $398.80 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $380.07 | 2020-2023 | Farxiga, Andexxa |
| Novartis Pharmaceuticals Corporation | $310.03 | 2022-2024 | |
| Pfizer INC. | $300.91 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $286.09 | 2020-2024 | Xarelto |
| Heartflow, INC. | $279.63 | 2024-2025 | |
| Medtronic, INC. | $261.63 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Azure Xt Dr Mri Surescan |
| Amgen INC. | $219.38 | 2021-2025 | Repatha, Repatha |
| Cook Medical LLC | $197.16 | 2020-2023 | Evolution |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $171.44 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $157.51 | 2023 | |
| Alnylam Pharmaceuticals INC. | $147.04 | 2024-2025 | Amvuttra |
| Allergan, INC. | $140.58 | 2022 | |
| Medtronic Vascular, INC. | $140.14 | 2019 | |
| Mentor Worldwide LLC | $138.09 | 2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Kerecis Limited | $125.65 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Esperion Therapeutics, INC. | $111.90 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $86.62 | 2024 | Arcalyst |
| Cleerly, INC. | $83.44 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Bayer Healthcare Pharmaceuticals INC. | $55.95 | 2021-2025 | |
| Kestra Medical Technology Services, INC. | $47.50 | 2022-2023 | Assure Wcd |
| Abiomed | $47.01 | 2022-2023 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.71 | 2022 | |
| Baxter Healthcare | $38.39 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Novo Nordisk INC | $19.25 | 2024 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals, LTD. | $16.28 | 2023 | Arcalyst |
| Inari Medical, INC. | $16.22 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Reflow Medical INC | $12.91 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Abelhad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.